The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s end stage renal disease ESRD drug market report forecasts the end stage renal disease ESRD drug market size to grow to $193.98 Billion by 2027, with a CAGR (compound annual growth rate) of more than 13%.

Learn More On The End Stage Renal Disease ESRD Drug Market Report 2023 – https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

End Stage Renal Disease ESRD Drug Market Size Forecast
The global end stage renal disease ESRD drug market is expected to grow from $101.73 billion in 2022 to $115.82 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global end stage renal disease (ESRD) drug market size is expected to grow to $193.98 billion in 2027 at a CAGR of 13.8%.

North America held the largest end stage renal disease ESRD drug market share.

Key End Stage Renal Disease ESRD Drug Market Driver ­– Rise In Cases Of Obesity And Diabetes
According to World Obesity, a US-based membership organisation representing national and regional associations dedicated to the study and management of obesity, there were 764 million obese people worldwide in 2020, with this figure expected to rise to 892 million in 2025 and then to 1,025 million in 2030 by March 2022. Furthermore, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organisation of over 230 national diabetes organisations, approximately 537 million people (20-79 years old) had diabetes in September 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. As a result, increased obesity and diabetes rates will fuel the market for end-stage renal disease (ESRD) medications.

Request for A Sample Of The Global End Stage Renal Disease ESRD Drug Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

Key End Stage Renal Disease ESRD Drug Market Trend – Product Innovations
To remain competitive in the end-stage renal disease (ESRD) medicine industry, major corporations are focusing on finding innovative treatments. For example, GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology company, announced in April 2022 that the US Food and Drug Administration (FDA) had accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the treatment of patients with chronic kidney disease anaemia (CKD). The new solution is based on Nobel Prize-winning research that demonstrated how cells sense and respond to oxygen availability.

End Stage Renal Disease ESRD Drug Market Segment
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalaemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

End Stage Renal Disease ESRD Drug Market Major Players and Strategies
Major players in the end stage renal disease ESRD drug market are Pfizer Inc., AstraZeneca Plc., Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, and Bristol-Myers Squibb Company.

Vifor Pharma, a Swiss pharmaceutical business, paid an unknown sum for Sanifit Therapeutics S.A. in November 2021. Vifor Pharma expands its portfolio of cutting-edge assets with this acquisition. Sanifit Therapeutics S.A. is a clinical-stage cardio-renal biopharmaceutical firm established in Spain that specialises on medicines for patients with end-stage kidney disease.

The End Stage Renal Disease ESRD Drug Global Market Report 2023 covers regional data on end stage renal disease ESRD drug market size, end stage renal disease ESRD drug market trends and drivers, opportunities, strategies, and end stage renal disease ESRD drug market competitor analysis. The countries covered in the end stage renal disease ESRD drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

A medicine used to treat end-stage renal disease (ESRD) is one that is used to treat a medical condition in which a person’s kidneys quit working permanently, necessitating a kidney transplant or a regular routine of long-term dialysis to save their lives. It is critical in the treatment and prevention of secondary issues in people with chronic kidney disease (CKD).

View More Reports Related To The End Stage Renal Disease ESRD Drug Market –
Renal Biomarkers Global Market Report 2023
Endoscope Reprocessing Global Market Report 2023
Drugs For Erectile Dysfunction Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: